IL312207A - formulations - Google Patents

formulations

Info

Publication number
IL312207A
IL312207A IL312207A IL31220724A IL312207A IL 312207 A IL312207 A IL 312207A IL 312207 A IL312207 A IL 312207A IL 31220724 A IL31220724 A IL 31220724A IL 312207 A IL312207 A IL 312207A
Authority
IL
Israel
Prior art keywords
liquid formulation
stable liquid
formulation according
similarity
seq
Prior art date
Application number
IL312207A
Other languages
English (en)
Hebrew (he)
Original Assignee
UCB Biopharma SRL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by UCB Biopharma SRL filed Critical UCB Biopharma SRL
Publication of IL312207A publication Critical patent/IL312207A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591Stabilisation, fragmentation
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183Amino acids, e.g. glycine, EDTA or aspartame
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
IL312207A 2021-10-21 2022-10-20 formulations IL312207A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB2115121.2A GB202115121D0 (en) 2021-10-21 2021-10-21 Formulations
PCT/EP2022/079182 WO2023067049A1 (en) 2021-10-21 2022-10-20 Formulations

Publications (1)

Publication Number Publication Date
IL312207A true IL312207A (en) 2024-06-01

Family

ID=78806158

Family Applications (1)

Application Number Title Priority Date Filing Date
IL312207A IL312207A (en) 2021-10-21 2022-10-20 formulations

Country Status (17)

Country Link
US (1) US20240415769A1 (https=)
EP (1) EP4419078A1 (https=)
JP (1) JP2024539265A (https=)
KR (1) KR20240099311A (https=)
CN (1) CN118119377A (https=)
AR (1) AR127421A1 (https=)
AU (1) AU2022372646A1 (https=)
CA (1) CA3235381A1 (https=)
CL (1) CL2024001229A1 (https=)
CO (1) CO2024006193A2 (https=)
GB (1) GB202115121D0 (https=)
GE (2) GEAP202416520A (https=)
IL (1) IL312207A (https=)
MX (1) MX2024004872A (https=)
PE (1) PE20241193A1 (https=)
TW (1) TW202323288A (https=)
WO (1) WO2023067049A1 (https=)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006100679A2 (en) 2005-03-22 2006-09-28 Quark Pharmaceuticals, Inc. Recombinant antibodies against human type ii transglutaminase and uses thereof
GB2490655A (en) 2011-04-28 2012-11-14 Univ Aston Modulators of tissue transglutaminase
GB201209096D0 (en) 2012-05-24 2012-07-04 Medical Res Council Technology Compounds
GB201411320D0 (en) 2014-06-25 2014-08-06 Ucb Biopharma Sprl Antibody construct
CN109563161A (zh) * 2016-02-03 2019-04-02 安口生物公司 用于提高抗体稳定性的缓冲制剂

Also Published As

Publication number Publication date
AU2022372646A1 (en) 2024-06-06
GEAP202416520A (en) 2024-07-25
AR127421A1 (es) 2024-01-24
GB202115121D0 (en) 2021-12-08
GEP20257800B (en) 2025-09-25
CN118119377A (zh) 2024-05-31
JP2024539265A (ja) 2024-10-28
TW202323288A (zh) 2023-06-16
CA3235381A1 (en) 2023-04-27
KR20240099311A (ko) 2024-06-28
US20240415769A1 (en) 2024-12-19
MX2024004872A (es) 2024-05-06
PE20241193A1 (es) 2024-06-03
EP4419078A1 (en) 2024-08-28
CL2024001229A1 (es) 2024-09-13
CO2024006193A2 (es) 2024-05-30
WO2023067049A1 (en) 2023-04-27

Similar Documents

Publication Publication Date Title
CN120938921A (zh) 含有高浓度抗vegf抗体的稳定蛋白质溶液剂型
EP3681483B1 (en) Process for lyophilized pharmaceutical formulation of a therapeutic protein
WO2011012637A4 (en) Subcutaneous anti-her2 antibody formulation
RU2011142184A (ru) Фармацевтический состав, содержащий молекулы антител с улучшенными свойствами
JP2005513110A (ja) Egf受容体に対する抗体を含む凍結乾燥製剤
PE20141159A1 (es) Metodos para tratar o prevenir trastornos relacionados con el colesterol
JP2022036932A5 (https=)
RU2011108025A (ru) Стабильный жидкий препарат антитела
EP2582394B1 (fr) Composition d'immunoglobulines humaines stabilisee
JP2012121894A (ja) Il−1アンタゴニスト製剤
RU2007119724A (ru) Композиции, содержащие эктинэсайдин и дисахарид
CL2024000232A1 (es) Composición farmacéutica de anticuerpo anti-pd-1 y uso de la misma
WO2022135395A1 (zh) 稳定的抗体制剂及其制备方法和应用
AR129062A1 (es) Composiciones farmacéuticas de proteínas terapéuticas y métodos de uso
JOP20220183A1 (ar) صياغات أجسام مضادة ضد tslp بشرية وطرائق علاج مرض التهابي
TWI877117B (zh) 包含掩蔽的抗原結合蛋白質之配製物及藥物組成物
SI2916866T1 (en) Form for bispecific T-cell activators (BiTE)
IL276911B2 (en) Variants of the carboxylation rate of antibodies
IL312207A (en) formulations
IL312211A (en) Formulations
RU2024113527A (ru) Композиции
RU2024113529A (ru) Составы
JP2024539265A5 (https=)
JP2024539502A5 (https=)
WO2025212547A1 (en) Methods of treating osteogenesis imperfecta